Repair Biotechnologies Inc. and Genevant Sciences Corp. have entered into a collaboration and nonexclusive license agreement to combine Repair’s Cholesterol Degrading Platform (CDP) mRNA technology with Genevant’s proprietary lipid nanoparticle (LNP) technology in the development of a potential novel treatment for atherosclerosis.

H. Lundbeck A/S and Iambic Therapeutics Inc. have entered into a strategic research collaboration focused on the discovery of a small-molecule therapeutic for the treatment of migraine. The collaboration will leverage Iambic’s artificial intelligence (AI)-powered drug discovery platform.

Axcelead Drug Discovery Partners (DDP) Inc. has entered into a strategic research and collaboration agreement with Eli Lilly & Co. for multiple drug discovery programs.

Nanovation Therapeutics Inc. has established a multiyear partnership with Novo Nordisk A/S to advance the development of novel genetic medicines targeting cardiometabolic and rare diseases. The partnership brings together Nanovation’s proprietary long-circulating lipid nanoparticle (lcLNP) technology for RNA delivery to cells outside of the liver, and Novo Nordisk’s expertise in cardiometabolic and rare disease R&D and clinical translation.

X-Chem Inc. has announced the achievement of a drug discovery milestone under its collaboration agreement with Astrazeneca plc.

Korro Bio Inc. has established a collaboration with Novo Nordisk A/S to advance the discovery and development of new genetic medicines, initially to treat cardiometabolic diseases. The collaboration brings together Novo Nordisk’s deep cardiometabolic disease understanding and drug development experience with Korro’s proprietary platform to develop RNA editing product candidates for two undisclosed targets.

Mid-Atlantic Biotherapeutics Inc. and Accelero Biostructures have entered into a research collaboration to identify novel USP30 inhibitors for neurological disorders and other indications.

Bayer AG and Nextrna Therapeutics Inc. have entered into a collaboration and license agreement to develop small-molecule therapeutics targeting long noncoding RNAs (lncRNAs) in oncology. Under the agreement, Bayer gains access to Nextrna’s differentiated approach to inhibit the function of lncRNAs by disrupting the interaction between lncRNAs and RNA-binding proteins (RBPs) with small molecules.